Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $2.80 USD
Change Today 0.00 / 0.00%
Volume 0.0
NSPH On Other Exchanges
Symbol
Exchange
NSPH is not on other exchanges.
As of 8:10 PM 08/4/15 All times are local (Market data is delayed by at least 15 minutes).

nanosphere inc (NSPH) Snapshot

Open
$2.82
Previous Close
$2.82
Day High
$2.87
Day Low
$2.74
52 Week High
08/5/14 - $28.40
52 Week Low
08/4/15 - $2.74
Market Cap
20.7M
Average Volume 10 Days
55.9K
EPS TTM
$-8.43
Shares Outstanding
7.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NANOSPHERE INC (NSPH)

Related News

No related news articles were found.

nanosphere inc (NSPH) Related Businessweek News

No Related Businessweek News Found

nanosphere inc (NSPH) Details

Nanosphere, Inc. develops, manufactures, and markets molecular diagnostic tests that can lead to earlier disease detection, optimal patient treatment, and enhanced healthcare economics. It offers a molecular diagnostics platform, Verigene System platform that enables clinicians to identify and treat the bacteria and viruses for complex, costly, and deadly infectious diseases. The Verigene System includes a bench-top molecular diagnostics workstation for genomic and protein testing. The Verigene System is used for testing infectious disease assays, human and pharmacogenetic assays, and ultra-sensitive protein assays. The company focuses on serving hospital-based laboratories and academic research institutions in the United States. Nanosphere, Inc. was founded in 1998 and is headquartered in Northbrook, Illinois.

169 Employees
Last Reported Date: 02/11/15
Founded in 1998

nanosphere inc (NSPH) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $330.0K
Chief Strategy Officer
Total Annual Compensation: $310.0K
Compensation as of Fiscal Year 2014.

nanosphere inc (NSPH) Key Developments

Nanosphere, Inc. Amends Certain Terms of Its $30 Million Term Loan Facility with NSPH Funding LLC

Nanosphere, Inc. announced that it has amended certain terms of its $30 million term loan facility with NSPH Funding LLC, an affiliate of Life Sciences Alternative Funding LLC, and SWK Funding LLC, as lenders. Nanosphere entered into the loan facility and immediately drew $20 million under the facility on May 14, 2015. Under the original terms of the loan facility, Nanosphere was subject to a condition precedent and a post-closing covenant that required Nanosphere to raise an aggregate of at least $4 million in net proceeds from equity financings prior to entering into the loan facility and an aggregate of at least $6 million in net proceeds either equity financings or licensing or strategic partnership transactions within eight months of May 14, 2015, pursuant to which Nanosphere raised an aggregate of $8 million in net proceeds from its preferred stock offerings in May and June 2015. Under the amended terms of the loan facility, the lenders have waived the requirement that Nanopshere raise an additional $2 million in consideration of certain adjustments to the reserve requirements under the loan facility.

Nanosphere, Inc. Announces New Studies Highlight Antibiotic Resistance Detection

Nanosphere, Inc. announced that seven studies evaluating the performance and clinical impact of select Verigene multiplex infectious disease tests were presented at the 115th General Meeting of the American Society for Microbiology, held last month in New Orleans, Louisiana. Three of these studies highlighted the superior performance and broad antibiotic resistance coverage of the Verigene Gram-Negative Blood Culture Test (BC-GN). Researchers from the Detroit Medical Center, the University of Michigan Health System and the Michigan Department of Community Health presented data that demonstrated the ability of BC-GN to rapidly and accurately detect three different multi-drug resistance genes that cause carbapenem-resistant Enterobacteriaceae (CRE), commonly referred to as "superbugs," in clinical samples. Researchers at Baylor University and med fusion described a 48-hour reduction in time to identification of gram-negative bacteria and resistance detection with BC-GN, which allowed for the optimization of antibiotic treatment for certain patients. Antimicrobial resistance is an immediate and severe public health threat that has garnered the attention of world leaders, including President Barack Obama, who specifically acknowledged the critical importance of rapid diagnostic tests in his recent fiscal year 2016 budget proposal as part of a historic $1.2 billion investment to combat antimicrobial resistance. Four additional studies presented at asm 2015 highlighted the accuracy and utility of the Verigene Gram-Positive Blood Culture Test (BC-GP), Verigene Enteric Pathogens Test (EP), and the research-use only Verigene Respiratory Pathogens Flex Test (RP Flex).

Nanosphere, Inc. Announces Executive Changes, Effective from June 12, 2015

On June 1, 2015, Ann Wallin, the interim chief financial officer, chief accounting officer and secretary of Nanosphere, Inc. resigned as an officer and employee of the company effective June 12, 2015. Ms. Wallin resigned to pursue other professional opportunities and her resignation did not arise from any disagreement on any matter relating to the company's operations, policies or practices. In connection with Ms. Wallin's resignation and effective June 12, 2015, the company has appointed Ms. Farzana Moinuddin, the company's Accounting Manager, as acting principal financial officer and Interim Chief Accounting Officer. On June 2, 2015, the company appointed Ms. Farzana Moinuddin, the company's Accounting Manager, as principal financial officer and Interim Chief Accounting Officer effective June 12, 2015. Ms. Moinuddin joined the company on May 7, 2014 as Accounting Manager. Prior to joining the company, from 2005 to 2014, Ms. Moinuddin served in various roles at Stericycle, Inc.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NSPH:US $2.80 USD 0.00

NSPH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
GenMark Diagnostics Inc $8.12 USD 0.00
Great Basin Scientific Inc $2.67 USD 0.00
Meridian Bioscience Inc $18.53 USD 0.00
Quidel Corp $20.85 USD 0.00
T2 Biosystems Inc $14.36 USD 0.00
View Industry Companies
 

Industry Analysis

NSPH

Industry Average

Valuation NSPH Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.1x
Price/Book 0.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NANOSPHERE INC, please visit www.nanosphere.us. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.